Trials / Completed
CompletedNCT01578135
French National Registry of Children Born Small for Gestational Age Treated With Somatropin
French National Longitudinal Prospective Follow-up of Children Born Small for Gestational Age and Treated With Norditropin SimpleXx (French Health Authorities Commitment)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 291 (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study is conducted in Europe. The aim of the study is to describe the patient population and therapeutic practices (study phase I), assess efficacy on growth and adult height and assess tolerance of somatropin (Norditropin® SimpleXx®) (study phase II)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | somatropin | Patients are to fill in a questionnaire at inclusion in registry |
| DRUG | somatropin | Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached |
Timeline
- Start date
- 2007-03-18
- Primary completion
- 2018-10-09
- Completion
- 2018-10-09
- First posted
- 2012-04-16
- Last updated
- 2022-10-20
Locations
1 site across 1 country: France
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01578135. Inclusion in this directory is not an endorsement.